Jiangxi Synergy Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of March 2026: 4.68%

Jiangxi Synergy Pharmaceutical Co Ltd asset resilience ratio. Jiangxi Synergy Pharmaceutical Co Ltd (300636) has an Asset Resilience Ratio of 4.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300636 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥155.13 Million
≈ $22.70 Million USD Cash + Short-term Investments

Total Assets

CN¥3.31 Billion
≈ $484.59 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Jiangxi Synergy Pharmaceutical Co Ltd (2024–2025)

Asset resilience ratio of Jiangxi Synergy Pharmaceutical Co Ltd from 2024 to 2025. This chart shows how Jiangxi Synergy Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 300636 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Jiangxi Synergy Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300636 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥155.13 Million 4.68%
Total Liquid Assets CN¥155.13 Million 4.68%

Asset Resilience Insights

  • Limited Liquidity: Jiangxi Synergy Pharmaceutical Co Ltd maintains only 4.68% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangxi Synergy Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangxi Synergy Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 26.45%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 11.84%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Bide Pharmatech Co. Ltd. A
SHG:688073
Drug Manufacturers - Specialty & Generic 9.46%
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
Drug Manufacturers - Specialty & Generic 20.61%
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
Drug Manufacturers - Specialty & Generic 30.38%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.42%

Jiangxi Synergy Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2024–2025)

Jiangxi Synergy Pharmaceutical Co Ltd asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Jiangxi Synergy Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 1.21% CN¥40.08 Million
≈ $5.87 Million
CN¥3.32 Billion
≈ $485.97 Million
+0.60pp
2024-12-31 0.60% CN¥20.05 Million
≈ $2.93 Million
CN¥3.32 Billion
≈ $485.75 Million
--
pp = percentage points

About Jiangxi Synergy Pharmaceutical Co Ltd

SHE:300636 China Drug Manufacturers - Specialty & Generic
Market Cap
$400.05 Million
CN¥2.73 Billion CNY
Market Cap Rank
#13035 Global
#3812 in China
Share Price
CN¥6.51
Change (1 day)
+0.00%
52-Week Range
CN¥6.30 - CN¥8.66
All Time High
CN¥15532.43
About

Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-… Read more